Who are Saxagliptin-Metformin XR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Linagliptin / Metformin Oral Tablet, Sitagliptin phosphate/metformin hydrochloride FDC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saxagliptin-metformin-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Saxagliptin-Metformin XR — Competitive Intelligence Brief

Saxagliptin-Metformin XR (Saxagliptin-Metformin XR) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor / Biguanide combination. Area: Diabetes.

phase 3 DPP-4 inhibitor / Biguanide combination DPP-4 enzyme; metformin targets mitochondrial glycerophosphate dehydrogenase and AMPK Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Saxagliptin-Metformin XR (Saxagliptin-Metformin XR) — Woman's. Saxagliptin inhibits DPP-4 to increase incretin levels and lower blood glucose, while metformin XR reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saxagliptin-Metformin XR TARGET	Saxagliptin-Metformin XR	Woman's	phase 3	DPP-4 inhibitor / Biguanide combination	DPP-4 enzyme; metformin targets mitochondrial glycerophosphate dehydrogenase and AMPK
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
Sitagliptin phosphate/metformin hydrochloride FDC	Sitagliptin phosphate/metformin hydrochloride FDC	Merck Sharp & Dohme LLC	marketed	DPP-4 inhibitor / biguanide combination	DPP-4 enzyme / metformin (AMPK pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor / Biguanide combination class)

Universidad de Guanajuato · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saxagliptin-Metformin XR — Competitive Intelligence Brief. https://druglandscape.com/ci/saxagliptin-metformin-xr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab